(redirected from DVT)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for thrombosis

Words related to thrombosis

the formation or presence of a thrombus (a clot of coagulated blood attached at the site of its formation) in a blood vessel

References in periodicals archive ?
The inclusion criteria were: 1) patients who were diagnosed with gynecological malignant tumor such as cervical cancer, endometrial cancer, ovarian cancer, and fallopian tube cancer, treated surgically or non-surgically, 2) patients who had no history of DVT, and 3) patients with complete clinical data.
The incidence of DVT is the highest in the first two weeks after surgery3.
Morbidity impact to the older adults is greater, with an accelerated rise in incidence of PE than DVT. (5)
An ultrasound scan or venogram (a contrast dye injected into your vein) can be also carried out to confirm DVT.
Continuous variables including age, BMI, and DVT were analyzed by the Student t-test.
DVT was diagnosed through ultrasound imaging with or without symptoms.[sup][4] Risk factors included age, gender, surgery/immobilization, chemotherapy/hormonal therapy, and pregnancy.
Allegro DVT is a provider of H.264/MPEG-4 AVC|SVC|MVC, H.265/HEVC, VP9 and AVS2 solutions, including industry standard compliance test suites, H.264/MPEG-4 AVC, H.265/HEVC and VP9 encoder, codec and decoder hardware (RTL) IPs.
Similarly, the clinical features of DVT are often non-specific, making it difficult to confidently exclude a thrombosis based on the physical examination alone.
To study the incidence of DVT in patients admitted to General Surgery ward with various surgical illnesses undergoing surgical management without any prophylactic anticoagulant therapy using Doppler studies.
Those studies examining the benefits of thromboprophylaxis in the setting of knee arthroscopy have all used low molecular weight heparin (LMWH) as the primary intervention with reductions in the risk of DVT ranging from 65% to 93%.
has announced that the FDA has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.
Accurate clinical diagnosis of deep venous thrombosis (DVT) is notoriously difficult, analogous to accurate clinical diagnosis of pulmonary embolism (PE).